Showing results (21-30 of 498) with videos related to
Sort By:
Pageof 50
Cancer Control : Journal of the Moffitt Cancer Center|October 1, 2013
Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapyGiao Q Phan, Steven A RosenbergClinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
BRAF Inhibition: Bridge or Boost to T-cell Therapy?Stephanie L Goff, Steven A RosenbergAcademic Pediatrics|October 24, 2012
Does the persistence of development delay predict receipt of early intervention services?Beth M McManus, Steven A RosenbergJournal for Immunotherapy of Cancer|April 10, 2025
Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the Surgery Branch, NCIStephanie L Goff, Steven A RosenbergProceedings of the National Academy of Sciences of the United States of America|September 24, 2004
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytesSteven A Rosenberg, Mark E DudleyNature Reviews. Cancer|September 3, 2003
Adoptive-cell-transfer therapy for the treatment of patients with cancerMark E Dudley, Steven A RosenbergJournal of Immunotherapy (Hagerstown, Md. : 1997)|December 17, 2003
Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccinationDaniel J Powell, Steven A RosenbergJournal of Immunology (Baltimore, Md. : 1950)|January 5, 2002
Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapyHung T Khong, Steven A RosenbergCancer Research|May 31, 2002
The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapyHung T Khong, Steven A RosenbergJournal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2002
Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2David M Weinreich, Steven A RosenbergPageof 50